evipedia.ai
← Back

CJC-1295 for Health & Longevity

Evidence Review created on 10/27/2026 using AI4L / Opus 5.5

Also known as: CJC-1295 with DAC, CJC-1295 DAC, DAC:GRF, CJC-1295 without DAC, CJC-1295 no DAC, Modified GRF (1-29), Mod GRF 1-29

Motivation

CJC-1295 is a lab-made peptide modeled on the brain hormone that tells the pituitary gland to release growth hormone. Its original form carries a chemical hook that attaches it to the main protein in blood, so one injection keeps signaling for about a week instead of minutes. It draws interest because the body’s growth hormone output falls with age, and CJC-1295 is promoted as a way to raise it from within rather than by injecting growth hormone itself.

A Canadian biotechnology company built it in the early 2000s and tested it in a few small human studies before development stopped. It never became an approved medicine, yet it is widely sold online as a “research chemical” and offered by peptide clinics, often paired with a second growth-hormone-releasing peptide, for body composition, sleep and healthy aging.

This review examines CJC-1295 for health and longevity: human data on hormone levels, indirect evidence from related compounds on body composition, thinking and sleep, the long-term risks of raising a growth signal, product quality and regulatory standing. A longevity plan implies long-term use, which makes these questions central.

Benefits - Risks - Protocol - Conclusion

Overviews of CJC-1295 and related analogues of growth hormone (GH)-releasing hormone (GHRH, the brain signal that prompts the pituitary to release GH), which raise insulin-like growth factor 1 (IGF-1, a growth signal made mainly by the liver in response to GH).

No dedicated content was found from Rhonda Patrick, Chris Kresser or Lifespan.io: their site searches and web searches returned nothing on CJC-1295. Life Extension discusses CJC-1295 only in one short paragraph of its Life Extension testosterone protocol, too brief to qualify as an in-depth item.

Grokipedia

  • CJC-1295

    A broad encyclopedic overview of CJC-1295’s structure, development history, human pharmacokinetics, U.S. compounding status and anti-doping listing, useful as a quick orientation though AI-generated and not peer reviewed.

Examine

No Examine article on CJC-1295 exists. Examine.com covers dietary supplements and nutrition; CJC-1295 is an unapproved injectable peptide, not a supplement.

ConsumerLab

No ConsumerLab article on CJC-1295 exists. ConsumerLab tests dietary supplements; CJC-1295 is an unapproved injectable peptide outside its testing scope.

Systematic Reviews

No systematic reviews or meta-analyses for CJC-1295 were found on PubMed as of October 27, 2026.

Neither the claimed effects nor the principal risks of CJC-1295 are represented by a systematic review or meta-analysis; the nearest syntheses cover tesamorelin and growth hormone itself.

Mechanism of Action

CJC-1295 copies the first 29 amino acids of GHRH, the active portion of the hormone, with four substitutions that protect it from dipeptidyl peptidase-4 (DPP-4, a blood enzyme that inactivates native GHRH within minutes), as described by ConjuChem’s own researchers (Jetté 2005). The original version adds a reactive linker, the Drug Affinity Complex (DAC), that bonds to albumin after injection; “CJC-1295 without DAC” (Mod GRF 1-29) is the same peptide without the linker.

  • Target and selectivity: binds GHRH receptors on somatotrophs (the GH-producing cells of the pituitary), raising GH and, downstream, IGF-1. Natural GH pulses persist, while the baseline between pulses rises (Ionescu 2006).
  • Half-life: 5.8–8.1 days for the DAC version in healthy adults, per sponsor-run trials whose authors included ConjuChem staff (Teichman 2006); the no-DAC form has no published human pharmacokinetic study, per a narrative review (Dominikowski 2026).
  • Distribution and metabolism: stays largely in the bloodstream bound to albumin; as a peptide it is expected to be broken down by protein-cleaving enzymes, with no known role for cytochrome P450 (CYP, the liver’s main drug-metabolizing enzymes). No human metabolism study exists.
  • Competing view: the rationale assumes restoring youthful GH output is beneficial. The opposing model holds that lower GH/IGF-1 signaling favors longevity: people with inherited GH-receptor deficiency (Laron syndrome) had almost no cancer or diabetes over 22 years (Guevara-Aguirre 2011), and higher IGF-1 predicted more disease in older UK Biobank participants (Zhang 2021).

Historical Context & Evolution

CJC-1295 was created in the early 2000s by ConjuChem, a Montreal biotechnology company, because native GHRH acts for minutes and treating GH deficiency with it required frequent injections. Binding the peptide to albumin produced a once-weekly candidate (Jetté 2005). In two placebo-controlled trials in healthy adults, single and repeated injections produced GH and IGF-1 rises lasting days to weeks (Teichman 2006).

ConjuChem then tested it against abdominal fat in people with HIV (human immunodeficiency virus) on antiretroviral therapy (drugs that suppress HIV). In July 2006 the phase 2 trial was stopped after a participant died, with the cause under investigation (aidsmap report); a company statement the next month, no longer online, reported that the attending physician judged undiagnosed coronary artery disease, not the drug, the most likely cause. The registry lists the trial as terminated without posted results (NCT00267527). Development ended, while tesamorelin, a daily GHRH analogue from another Canadian company, went on to approval for that indication (Egrifta WR label).

Interest for health optimization grew from parallels between aging and adult GH deficiency, and from the idea that stimulating the pituitary offers advantages over injecting GH (Merriam 2003). By 2009 the peptide was circulating in unlicensed products (Henninge 2010). The U.S. Food and Drug Administration (FDA) placed it in its category of compounding substances with significant safety risks; after the nomination was withdrawn, FDA lists it as withdrawn, with those concerns still noted (FDA safety page). FDA’s advisory committee reviewed its forms in December 2024 (FDA meeting page).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no trial of CJC-1295 has measured a clinical outcome, and the outcome trials that exist tested other GHRH analogues, which is indirect evidence.

Medium 🟩 🟩

No benefit reaches Medium: the only CJC-1295 trials in people measured hormone levels, which are not clinical outcomes or validated surrogates of health.

Low 🟩

Less visceral fat

Visceral fat, packed around abdominal organs, tracks with cardiometabolic risk. Tesamorelin, a different daily GHRH analogue, reduced it in two phase 3 trials co-authored by manufacturer staff (Falutz 2010) and in a later single-center trial (Stanley 2014), both in adults with HIV. Evidence is indirect: different compound and population.

Magnitude: Visceral fat area fell 24 cm² vs rose 2 cm² on placebo at 26 weeks, a 15.4% treatment effect (Falutz 2010); treatment effect −42 cm² (95% CI, confidence interval, the range likely to hold the true effect: −71 to −14) over 6 months (Stanley 2014).

Less liver fat

Tesamorelin lowered liver fat over 12 months in adults with HIV and fatty liver disease (Stanley 2019). Evidence is indirect: a different GHRH analogue, given daily, in a disease population; CJC-1295 has never been tested on liver fat.

Magnitude: Hepatic fat fraction 4.1 percentage points lower than placebo (95% CI −7.6 to −0.7) at 12 months; 35% vs 4% on placebo fell below 5% liver fat (Stanley 2019).

More lean body mass

GHRH analogues raise lean mass: a meta-analysis of tesamorelin trials in HIV (Badran 2026) and a trial in older adults (Baker 2012) agree. Part of the gain may be water; a systematic review of GH in older adults could not pool strength outcomes (Liu 2007). Evidence is indirect: other compounds.

Magnitude: Lean body mass 1.42 kg higher than placebo (95% CI 1.13 to 1.71) across tesamorelin randomized controlled trials (Badran 2026); lean mass +3.7% vs placebo in older adults over 20 weeks (Baker 2012).

Better thinking in older adults ⚠️ Conflicted

In a 20-week blinded trial in 152 adults aged 55–87, some with mild cognitive impairment (MCI, decline short of dementia), tesamorelin improved executive function (Baker 2012). An open-label tesamorelin trial in HIV-related impairment found no between-group difference (Ellis 2025). Indirect: a different compound; the larger blinded trial carries more weight.

Magnitude: Executive-function composite improved vs placebo with effect size f = 0.37 (a standardized between-group difference of medium size); the paper reports no absolute score difference (Baker 2012). The HIV trial found no difference between groups (Ellis 2025).

Deeper sleep ⚠️ Conflicted

Night-time intravenous GHRH reduced awakenings in older adults (Guldner 1997) but increased non-rapid-eye-movement sleep only in men (Antonijevic 2000). Bedtime tesamorelin for 20 weeks left sleep quality unchanged (Baker 2012). Evidence is indirect: native hormone, different route. Net: no durable sleep benefit shown.

Magnitude: Direction only: fewer nocturnal awakenings after intravenous GHRH in older adults (Guldner 1997), less non-rapid-eye-movement sleep in women (Antonijevic 2000), and no difference from placebo in sleep quality after 20 weeks of tesamorelin (Baker 2012); the literature reports no outcome figure for a sleep benefit.

Speculative 🟨

Raised GH and IGF-1 as a longevity strategy

CJC-1295 reliably raises GH and IGF-1 in people (Teichman 2006). IGF-1 is not a validated marker of healthier aging; in UK Biobank both low and high levels predicted earlier death (Xie 2021).

Tissue repair, recovery and skin

Claims of faster injury healing, quicker recovery and firmer skin rest on growth hormone physiology and user reports; no controlled study of CJC-1295 has measured these outcomes. The basis is mechanistic and anecdotal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No common variant has been studied for response to CJC-1295. Rare inherited defects of the GHRH receptor or GH receptor would blunt or abolish any effect, since the peptide works only through the body’s own GH pathway.
  • Baseline biomarkers: People with IGF-1 in the low-normal range for age have the most headroom; those already high-normal gain little and move toward the range linked with higher mortality (Xie 2021).
  • Sex differences: A GHRH analogue raised lean mass, insulin sensitivity and well-being in older men but not women (Khorram 1997); GHRH increased non-rapid-eye-movement sleep in men and reduced it in women (Antonijevic 2000).
  • Pre-existing conditions: Excess visceral and liver fat is where related-compound benefits were shown. Tesamorelin’s label excludes people whose pituitary-control system is disrupted, e.g., by pituitary surgery, tumor or head irradiation (Egrifta WR label); with no working GH-producing pituitary cells, the peptide has no target.
  • Age: The aging pituitary still responds to GHRH, per a review (Merriam 2003), and older adults showed cognitive gains with tesamorelin (Baker 2012); GHRH’s sleep effect is weaker in older adults (Guldner 1997).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: CJC-1295’s only controlled human data come from one sponsor’s small, short trials, and the replicated adverse events are documented for tesamorelin and growth hormone, which is indirect evidence.

Medium 🟥 🟥

Injection-site reactions

Redness, itching or pain where the peptide is injected. A review reports mild local effects in the CJC-1295 trials in healthy adults (Dominikowski 2026), and injection-site reactions are the commonest adverse reaction of tesamorelin (Egrifta WR label). They are usually mild and transient.

Magnitude: 17% on tesamorelin vs 6% on placebo over 26 weeks (Egrifta WR label); no CJC-1295 rate with a comparison group is published (Teichman 2006).

Low 🟥

Raised heart rate and vasodilatory reactions ⚠️ Conflicted

Flushing (blood-vessel widening) with a faster pulse. FDA lists increased heart rate and a systemic vasodilatory reaction as serious events (FDA safety page); a participant died in a 2006 trial, cause unconfirmed (aidsmap report). The sponsor’s placebo-controlled trials reported no serious adverse reactions (Teichman 2006). Net: a plausible, unquantified signal.

Magnitude: Not quantified in available studies. The trial abstract and the FDA summary give no event rates for CJC-1295, and no comparison-group rate has been published (Teichman 2006).

Glucose intolerance and diabetes ⚠️ Conflicted

GH counters insulin. On tesamorelin, more patients reached diabetic-range glycated hemoglobin (HbA1c, a three-month blood sugar average) than on placebo; a 12-week, manufacturer-co-authored trial in type 2 diabetes found no worsening (Clemmons 2017). Indirect: a different analogue. Net: a modest but real class risk.

Magnitude: HbA1c ≥6.5% in 5% on tesamorelin vs 1% on placebo at 26 weeks (hazard ratio, the relative event rate over time, 3.3; 95% CI 1.4 to 9.6) (Egrifta WR label); no difference in glycemic control vs placebo in type 2 diabetes (Clemmons 2017).

Fluid retention, joint pain and carpal tunnel syndrome

GH causes water retention, producing swelling, joint and muscle pain and carpal tunnel syndrome (nerve compression at the wrist). These are common on tesamorelin (Egrifta WR label) and on GH in healthy older adults (Liu 2007). Indirect: other compounds; usually reversible on stopping.

Magnitude: Joint pain 13% vs 11%, peripheral swelling 6% vs 2% and muscle pain 6% vs 2% on tesamorelin vs placebo over 26 weeks (Egrifta WR label); GH in older adults raised soft-tissue swelling, joint pain and carpal tunnel syndrome vs no GH (Liu 2007).

Promotion of cancer growth

IGF-1 promotes cell growth and survival. In a meta-analysis, higher circulating IGF-1 was associated with prostate and premenopausal breast cancer (Renehan 2004), and tesamorelin’s label bars use with active cancer (Egrifta WR label). Indirect and observational (natural IGF-1 levels); CJC-1295 trials were far too short to show any cancer signal.

Magnitude: Odds ratio (how much more common cancer was at higher IGF-1) 1.49 (95% CI 1.14 to 1.95) for prostate and 1.65 (1.26 to 2.08) for premenopausal breast cancer, 75th vs 25th IGF-1 percentile (Renehan 2004).

Higher mortality at high IGF-1 levels

In 380,997 UK Biobank adults, IGF-1 related to death in a U-shape: both lowest and highest levels carried more risk (Xie 2021); high IGF-1 was riskier with older age (Zhang 2021). Indirect and observational: natural levels, not peptide-raised ones.

Magnitude: Highest vs fifth IGF-1 decile (tenths of participants ranked by IGF-1): 17% higher all-cause mortality (95% CI 7% to 28%) and 38% higher cardiovascular mortality (95% CI 11% to 71%) (Xie 2021).

Allergic reactions and anti-drug antibodies ⚠️ Conflicted

FDA flags immunogenicity (immune-provoking potential) for compounded CJC-1295 (FDA safety page). On tesamorelin, hypersensitivity occurred and about half of patients formed antibodies, many cross-reacting with the body’s own GHRH (Egrifta WR label); a long-acting GHRH study found none (Munafo 2005). Indirect: other compounds. Net: a plausible, unquantified class risk.

Magnitude: Hypersensitivity in 4% and anti-drug antibodies in 50% of tesamorelin-treated patients at 26 weeks, about 60% of them cross-reacting with native GHRH; no comparison-group rate given (Egrifta WR label); no antibodies to GHRH detected with a polyethylene glycol-linked GHRH (Munafo 2005).

Speculative 🟨

Mislabeled or contaminated gray-market product

Seized products contained the short-acting no-DAC peptide sold under the CJC-1295 name, or glycine-modified versions of it (Henninge 2010; Gajda 2019). Harm from such products has not been documented; the basis is laboratory analysis only.

Pituitary overstimulation

In mice lacking GHRH, daily CJC-1295 raised pituitary GH-gene activity and expanded GH-producing cells (Alba 2006, ConjuChem co-authored). Whether years of use enlarge a normal human pituitary is unknown; the basis is animal data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Inherited cancer syndromes (e.g., BRCA1/2, genes that repair DNA damage; Lynch syndrome, an inherited colon-cancer syndrome) raise the stakes of IGF-1’s growth-promoting action; this concern is inferred from mechanism (Renehan 2004).
  • Baseline biomarkers: Prediabetic fasting glucose or HbA1c, high-normal IGF-1, or an elevated prostate-specific antigen (PSA, a prostate cancer screening marker) raise the risk that glucose, growth-signal or prostate concerns become clinically relevant.
  • Sex differences: Women reported more adverse events than men on tesamorelin and needed more dose reductions (Baker 2012); women also showed reduced non-rapid-eye-movement sleep with GHRH (Antonijevic 2000).
  • Pre-existing conditions: Diabetes, prior cancer and diabetic retinopathy (eye damage from diabetes, which IGF-1 may worsen) are flagged in the tesamorelin label (Egrifta WR label); coronary disease and carpal tunnel syndrome are inferred to raise risk.
  • Age: In older adults GH raised swelling, joint pain and carpal tunnel syndrome, with only a trend toward more diabetes (Liu 2007), and high IGF-1 became more harmful with age (Zhang 2021).

Key Interactions & Contraindications

Documented interactions:

  • Glucocorticoids (cortisol-like steroids; cortisone acetate, prednisone): GH blocks 11β-HSD1 (11β-hydroxysteroid dehydrogenase type 1, the enzyme activating them), so people on replacement for adrenal insufficiency (too little cortisol) may need higher maintenance or stress doses. Documented for tesamorelin (Egrifta WR label), not tested with CJC-1295.
  • CYP-metabolized drugs (sex steroids, anticonvulsants [anti-seizure drugs] such as carbamazepine, cyclosporine): GH may alter their clearance, changing blood levels; the label calls for monitoring. Documented for tesamorelin (Egrifta WR label).
  • Glucose-lowering drugs (insulin, metformin, sulfonylureas such as glipizide): GH counters insulin action, so doses may need adjustment when GH-axis stimulation starts, or glucose control worsens; glucose monitoring mitigates. Documented for somatropin (Genotropin label), not tested with CJC-1295.
  • Oral estrogens (ethinyl estradiol, oral estradiol, conjugated estrogens): women on oral estrogen may need a larger somatropin dose to reach the treatment goal, so GH-axis stimulation may have less effect; IGF-1 monitoring mitigates. Documented for somatropin (Genotropin label), not tested with CJC-1295.
  • Simvastatin and ritonavir: No clinically relevant interaction found; in healthy volunteers tesamorelin changed their exposure by at most 15% (simvastatin acid), which the label judged not significant (Egrifta WR label).
  • Other GH secretagogues (ipamorelin, hexarelin, GHRP-6 [growth hormone-releasing peptide 6]): these trigger GH release via the ghrelin (gut-hormone) receptor; GHRP plus native GHRH released GH synergistically in healthy men (Bowers 1990). Consequence: higher IGF-1, swelling and glucose effects; one agent at a time limits this.
  • Thyroid hormone (levothyroxine): GH stimulation can unmask or worsen central hypothyroidism (underactive thyroid of pituitary origin), changing replacement needs; periodic thyroid tests with dose adjustment mitigate. Documented for somatropin (Genotropin label), not tested with CJC-1295.
  • Arginine (supplement): arginine potentiated the GH response to native GHRH in young and older adults (Ghigo 1990), so it may raise GH and IGF-1 further; IGF-1 monitoring mitigates. Tested as a 30 g intravenous infusion, not oral supplements.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Growth hormone (somatropin) or IGF-1 analogues (mecasermin): additive IGF-1 elevation with compounded fluid-retention and glucose effects; IGF-1 monitoring mitigates.
  • Somatostatin analogues (octreotide, lanreotide): somatostatin (a hormone that halts pituitary GH release) blunts the peptide’s effect.
  • Testosterone and anabolic steroids (testosterone cypionate, nandrolone): additive fluid retention and blood-pressure rise; blood pressure and swelling checks mitigate.
  • Over-the-counter decongestants (pseudoephedrine, phenylephrine): additive heart-rate rise on top of the peptide’s reported tachycardia (abnormally fast heart rate); avoiding them around dosing mitigates.
  • Over-the-counter high-dose niacin (nicotinic acid): additive insulin resistance and flushing; glucose monitoring mitigates.
  • Other supplements raising GH (ornithine, alpha-GPC [a choline compound]): additive GH stimulation via reduced somatostatin tone or cholinergic (acetylcholine-driven nerve) signaling; raised IGF-1 is the main consequence; IGF-1 monitoring mitigates.

Populations who should avoid CJC-1295:

  • Active cancer or cancer under treatment: contraindicated for tesamorelin because induced GH is a growth factor (Egrifta WR label); CJC-1295 is inferred to carry the same concern.
  • Pregnancy: contraindicated for tesamorelin because of possible fetal harm (Egrifta WR label).
  • Disrupted hypothalamic-pituitary axis (the brain-to-pituitary hormone control chain; hypophysectomy, surgical pituitary removal; hypopituitarism, pituitary hormone deficiency; pituitary tumor; head irradiation or trauma): contraindicated for tesamorelin (Egrifta WR label).
  • Acute critical illness (prolonged intensive care after cardiac or abdominal surgery, multiple trauma, respiratory failure): high-dose GH roughly doubled in-hospital mortality (Takala 1999); the tesamorelin label warns likewise (Egrifta WR label).
  • Diabetes with retinopathy: IGF-1 rises may worsen retinopathy; the tesamorelin label requires monitoring (Egrifta WR label).
  • Competitive athletes under anti-doping rules: CJC-1295 is named as a prohibited growth-hormone releasing factor under section S2 of the World Anti-Doping Agency (WADA) list (WADA Prohibited List); a WADA-accredited laboratory identified it in seized products (Henninge 2010).

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Baseline cancer screening: Up-to-date age-appropriate screening (e.g., PSA under 4 ng/mL, mammogram within 2 years, as required in a current GHRH-analogue trial (NCT06554717)) reduces the chance of feeding an undetected tumor.
  • IGF-1 ceiling: Rechecking IGF-1 at 4–6 weeks and stopping if it stays above +3 standard deviation scores (SDS, distance from the age-matched average) limits growth-signal and cancer concerns (Egrifta WR label).
  • Glucose surveillance: Fasting glucose and HbA1c at baseline and every 3 months; reconsidering use if glucose intolerance develops (Egrifta WR label) mitigates diabetes risk.
  • Lowest effective dose: Staying at or below the 30–60 µg/kg range best tolerated in trials (Teichman 2006) reduces flushing and heart-rate reactions.
  • Pulse and blood-pressure check: Measuring resting heart rate and blood pressure after the first injections, and stopping with palpitations or fainting, mitigates the vasodilatory and tachycardia risk.
  • No stacking: Using one GH-axis agent at a time avoids additive IGF-1, swelling and glucose effects.
  • Symptom stop rules: Stopping for persistent hand or ankle swelling, hand numbness or new joint pain prevents progression of fluid retention and carpal tunnel syndrome.
  • Allergy response: Stopping at the first hives, rash or generalized itching prevents escalation of hypersensitivity (Egrifta WR label).
  • Verified, sterile supply: Identity-tested product and sterile injection technique reduce mislabeling, contamination and injection-site infection.

Therapeutic Protocol

Timing, cycling, titration and other parameters given without a citation reflect common practice.

  • Trial regimen (with DAC): 30 or 60 µg/kg subcutaneously, weekly or every two weeks, in healthy adults (Teichman 2006); 60 or 90 µg/kg single doses in young men (Ionescu 2006).
  • Online regimen (with DAC): 1–2 mg per week in one or two injections, in 8–16-week cycles, as a narrative review compiled from bodybuilding protocols (Dominikowski 2026).
  • Online regimen (without DAC): 100–200 µg per injection once or twice daily, often with ipamorelin; no human trial supports it, per the same narrative review (Dominikowski 2026).
  • Clinic stacking approach: Physician Craig Koniver, whose clinic prescribes peptide stacks, described pairing CJC-1295 with ipamorelin, hexarelin or GHRP-6 (each about 100 µg), at bedtime (hexarelin in the morning), five days on and two off (Huberman Lab episode).
  • Approved-analogue alternative: Tesamorelin 1.28 mg subcutaneously daily is the labeled GHRH-analogue regimen, with randomized-trial data (Egrifta WR label).
  • No-stimulation alternative: A systematic review concluded GH cannot be recommended as an aging therapy in healthy older adults (Liu 2007); under this conventional approach, adults without GH deficiency receive no GH-axis stimulation.
  • Time of day: The no-DAC form is taken at bedtime to coincide with the natural night-time GH pulse, away from food; timing matters little for the weekly DAC form.
  • Half-life: 5.8–8.1 days for CJC-1295 with DAC (Teichman 2006); the no-DAC form is short-acting, but its human half-life has not been measured.
  • Single vs split dosing: The DAC form is a single weekly injection; the no-DAC form is split into one to three daily injections to mimic pulses.
  • Genetic polymorphisms: No pharmacogenetic variant is known to guide dosing; the peptide has no known CYP pathway, so CYP2D6 or CYP3A4 (two major drug-metabolizing liver enzymes) status is irrelevant.
  • Sex differences: Women had more adverse events and dose reductions on tesamorelin (Baker 2012), a reason practitioners cite for lower starting doses in women.
  • Age: Older adults respond hormonally, and GH in healthy older adults caused swelling, joint pain and carpal tunnel syndrome (Liu 2007); starting at the low end of the range is common practice.
  • Baseline biomarkers: Baseline IGF-1 sets the headroom; with a high-normal starting value, practitioners use a lower dose or none.
  • Pre-existing conditions: Prediabetes, cancer history or pituitary disease change the calculus; an intact pituitary is required for any effect (Ionescu 2006).

Discontinuation & Cycling

  • Short-term, not lifelong: Published trials gave CJC-1295 for at most 49 days (Teichman 2006); a planned 12-week trial was terminated without results (NCT00267527). No data support continuous long-term use, so time-limited cycles are typical.
  • Withdrawal effects: None described. With the DAC form, IGF-1 stays above baseline for up to about four weeks after dosing (Teichman 2006); after tesamorelin, IGF-1 returned to baseline within 10 weeks (Baker 2012).
  • Tapering: Not required; the peptide preserves natural GH pulsatility (Ionescu 2006), so abrupt stopping is not expected to leave the pituitary suppressed.
  • Cycling: Online protocols use 8–16 weeks on and 4–6 weeks off, per a review (Dominikowski 2026). With a nightly GHRH analogue, IGF-1 drifted back toward baseline by 16 weeks (Khorram 1997), suggesting waning response; cycling’s value is untested.
  • Benefit persistence: Gains attributed to GHRH analogues, such as lower body fat, are expected to fade after stopping, as IGF-1 returns to baseline.

Sourcing and Quality

  • No approved product: Neither CJC-1295 form is an approved medicine, per a narrative review (Dominikowski 2026), and FDA lists it among withdrawn compounding nominations with significant safety concerns (FDA safety page).
  • Compounding pharmacies: Under federal law, compounders may use only bulk substances with a monograph, an approved-drug component, or a 503A-list listing from FDA-registered suppliers (FDA 503A page); CJC-1295 meets none.
  • Research-chemical market: Most supply is sold “for research use only.” Seized products contained the no-DAC peptide marketed as CJC-1295, or glycine-modified versions of it (Henninge 2010; Gajda 2019).
  • What to look for: A lot-specific certificate of analysis with mass-spectrometry identity, high-performance liquid chromatography purity, endotoxin (bacterial toxin) and sterility results, and labeling that states DAC or no-DAC explicitly.
  • Approved alternative: Tesamorelin (Egrifta WR, Theratechnologies) is the only approved GHRH analogue among these peptides, per a narrative review (Dominikowski 2026), and is manufactured under pharmaceutical standards (Egrifta WR label).
  • Handling: Freeze-dried peptide is reconstituted with bacteriostatic water and refrigerated; repeated vial puncture raises contamination risk.

Practical Considerations

  • Time to effect: GH and IGF-1 rise within days of an injection (Teichman 2006); fat and lean-mass changes with tesamorelin were measured at 20 weeks (Baker 2012) and 26 weeks (Falutz 2010).
  • Common pitfalls: Confusing DAC and no-DAC products; reading flushing as proof of effect, which Koniver warns against (Huberman Lab episode); stacking several secretagogues; skipping IGF-1 and glucose checks; expecting strength gains.
  • Regulatory status (U.S.): No approved product, per a narrative review (Dominikowski 2026); FDA lists it as a withdrawn compounding nomination with safety concerns (FDA safety page), outside the substances compounders may use (FDA 503A page).
  • Anti-doping status: Named as a prohibited growth-hormone releasing factor under section S2 of the WADA list (WADA Prohibited List); a WADA-accredited laboratory identified it in seized products (Henninge 2010).
  • Payer incentives: No insurer or health system reimburses CJC-1295, and tesamorelin is labeled only for HIV-associated abdominal fat (Egrifta WR label), so payer cost incentives are not a source of bias in guidance on longevity use.
  • Access: Lawful pharmaceutical-grade supply is essentially unavailable; gray-market product is inexpensive but of unverified identity and sterility.

Interaction with Foundational Habits

  • Sleep: Direction: direct but inconsistent. GH is released mainly in deep sleep, and night-time GHRH infusions reduced awakenings in older adults (Guldner 1997), but bedtime tesamorelin left sleep quality unchanged (Baker 2012). Protecting sleep remains the stronger natural GH stimulus.
  • Nutrition: Direction: blunting. Carbohydrate-driven insulin and glucose spikes suppress GH release, so GH-releasing peptides are taken at least 45 minutes from food (Huberman Lab episode). Adequate protein supports lean mass; added sugar compounds the glucose risk.
  • Exercise: Direction: potentiating in theory. Exercise is itself a GH stimulus, and a systematic review found GH raises lean mass but could not pool strength outcomes (Liu 2007), so training supplies the functional benefit; a trial combining tesamorelin with exercise is under way (NCT06554717).
  • Stress management: Direction: indirect. A narrative review notes that, unlike ghrelin-mimicking peptides, GHRH analogues do not raise cortisol or prolactin (Dominikowski 2026); chronic stress and high cortisol blunt GH secretion, so stress control supports the peptide’s target pathway.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes the reference point against which any change is judged and screens out people at higher risk. It covers IGF-1, fasting glucose, HbA1c and fasting insulin, a lipid panel, resting heart rate and blood pressure, PSA in men, and body composition by dual-energy X-ray absorptiometry (DEXA, a low-dose body scan), together with up-to-date cancer screening. In common practice, abnormal glucose, high-normal IGF-1 or an unexplained PSA rise is investigated before a first dose.

Ongoing monitoring follows a fixed cadence: IGF-1, glucose, heart rate and blood pressure at 4–6 weeks; then IGF-1, HbA1c, lipids and PSA every 3 months while in use; DEXA at 6 months; and IGF-1 again 4–6 weeks after stopping. Success means the targeted outcome, such as less visceral fat, improves while IGF-1 stays below the label ceiling and glucose remains normal.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Below +3 SDS for age and sex, per the Egrifta WR label Expected to change; safety check Label advises considering stopping above +3 SDS (Egrifta WR label); conventional reference range is roughly −2 to +2 SDS, lab-specific; DAC dosing keeps levels raised for weeks
Fasting glucose 70–99 mg/dL (standard reference range) Safety check Fasting 8–12 hours; morning draw
HbA1c Below 5.7% (standard reference range) Safety check Label advises evaluating glucose before and during use and reports diabetic-range values at ≥6.5% (Egrifta WR label)
Fasting insulin About 2.6–24.9 µIU/mL, lab-specific (standard reference range) Safety check Rose with tesamorelin in MCI (Baker 2012); interpreted together with fasting glucose; change from own baseline is tracked
Triglycerides Below 150 mg/dL (standard reference range) Expected to change Fell with tesamorelin (Falutz 2010); fasting lipid panel
PSA (men) Below 4.0 ng/mL (standard reference range) Safety check Rise from own baseline is tracked; ejaculation and cycling in the 48 hours before testing can raise PSA
Resting heart rate 60–100 beats/min (standard reference range) Safety check FDA lists increased heart rate among serious events (FDA safety page); measured seated, after the first injections
Body composition (DEXA) No established target; track change from own baseline Expected to change Visceral fat and lean mass changed with tesamorelin (Badran 2026); the same scanner is used each time for comparability

Qualitative markers:

  • Sleep quality and night-time awakenings
  • Swelling of hands, feet or ankles
  • Joint or muscle pain
  • Numbness or tingling in the hands
  • Flushing or palpitations after injection
  • Injection-site redness, itching or lumps
  • Energy, recovery from training and waist circumference

Emerging Research

  • No active CJC-1295 trials: The only registered trial, a phase 2 study of CJC-1295 for visceral fat in HIV (NCT00267527), was terminated in 2006 with no results posted; no CJC-1295 trial is ongoing.
  • TRIUMPH, tesamorelin plus exercise: Phase 2, 100 adults aged 50–80 with HIV and frailty; primary endpoint chair-stand time; recruiting, completion expected 2028 (NCT06554717). A positive result would support GHRH-axis stimulation for function (indirectly); a null result would weaken the lean-mass-to-function rationale.
  • Tesamorelin after nerve injury: Phase 2, 36 participants, pinch-strength primary endpoint; recruiting, completion expected 2027 (NCT03150511). A positive result would lend indirect support to repair claims; a null result would weaken them.
  • IGF-1 and aging: UK Biobank analyses suggest high IGF-1 becomes harmful with age (Zhang 2021; Xie 2021); trials with hard outcomes could weaken or strengthen the case for raising IGF-1 in older adults.
  • Regulatory reassessment: FDA’s advisory committee reviewed CJC-1295 for the compounding list in December 2024 (FDA meeting page); future FDA action would change lawful access but not the evidence base.

Conclusion

CJC-1295 is an injectable lab-made peptide that prompts a gland at the base of the brain to release more of the body’s own growth hormone, for about a week per dose in its long-acting form. Its one firmly established effect in people is that hormonal rise. Every health benefit claimed for it, including less abdominal and liver fat, more lean mass, sharper thinking in older adults and deeper sleep, rests on studies of related compounds, mainly an approved daily cousin, with mixed results for sleep. No study has measured how CJC-1295 itself affects any health outcome, and no long-term safety data exist.

The risks run in parallel. The developer’s small trials and the regulator’s review point to flushing, a faster pulse and injection-site reactions, and the only later trial was halted after a participant died, a death the attending physician judged unrelated to the drug. Related compounds add fluid retention, joint pain and a modest rise in blood sugar problems. Over the long horizon that matters for longevity, persistently high levels of the growth signal this peptide raises are linked with some cancers and earlier death in older adults, while lower lifelong signaling is linked with protection.

The evidence base is thin, dated and largely produced by the company that developed the compound, and products sold today often come from unregulated suppliers. For an adult focused on healthy longevity, CJC-1295 remains an experimental way of pushing a growth pathway whose long-term balance of benefit is itself contested.

Top - Benefits - Risks - Protocol